159 related articles for article (PubMed ID: 34710755)
1. Myricetin exhibit selective anti-lymphoma activity by targeting BTK and is effective via oral administration in vivo.
Song X; Rao H; Guo C; Yang B; Ren Y; Wang M; Li Y; Cao Z; Pei J
Phytomedicine; 2021 Dec; 93():153802. PubMed ID: 34710755
[TBL] [Abstract][Full Text] [Related]
2. Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma.
He Y; Li J; Ding N; Wang X; Deng L; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Song Y; Zhu J
J Exp Clin Cancer Res; 2019 Feb; 38(1):86. PubMed ID: 30777096
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia.
Wu H; Hu C; Wang A; Weisberg EL; Chen Y; Yun CH; Wang W; Liu Y; Liu X; Tian B; Wang J; Zhao Z; Liang Y; Li B; Wang L; Wang B; Chen C; Buhrlage SJ; Qi Z; Zou F; Nonami A; Li Y; Fernandes SM; Adamia S; Stone RM; Galinsky IA; Wang X; Yang G; Griffin JD; Brown JR; Eck MJ; Liu J; Gray NS; Liu Q
Leukemia; 2016 Jan; 30(1):173-81. PubMed ID: 26165234
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological activity of imidazole group-substituted arylaminopyrimidines (IAAPs) as potent BTK inhibitors against B-cell lymphoma and AML.
Li S; Wu B; Zheng X; Wang C; Zhao J; Sun H; Sun X; Tang Z; Yuan H; Chen L; Ma X
Bioorg Chem; 2021 Jan; 106():104385. PubMed ID: 33272709
[TBL] [Abstract][Full Text] [Related]
5. Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma.
Ding N; Li X; Shi Y; Ping L; Wu L; Fu K; Feng L; Zheng X; Song Y; Pan Z; Zhu J
Oncotarget; 2015 Jun; 6(17):15122-36. PubMed ID: 25944695
[TBL] [Abstract][Full Text] [Related]
6. The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.
Li J; Wang X; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Pan Z; Ding N; Song Y; Zhu J
Int J Cancer; 2018 Jan; 142(1):202-213. PubMed ID: 28905990
[TBL] [Abstract][Full Text] [Related]
7. Eriocalyxin B induces apoptosis in lymphoma cells through multiple cellular signaling pathways.
Zhang YW; Jiang XX; Chen QS; Shi WY; Wang L; Sun HD; Shen ZX; Chen Z; Chen SJ; Zhao WL
Exp Hematol; 2010 Mar; 38(3):191-201. PubMed ID: 20045442
[TBL] [Abstract][Full Text] [Related]
8. Anlotinib Inhibits Proliferation and Induces Apoptosis in B-cell Acute Lymphoblastic Leukemia by Targeting the BTK and AKT/mTOR Pathway.
Shi X; Li S; Tang S; Lu Y
Anticancer Agents Med Chem; 2023; 23(12):1397-1405. PubMed ID: 36856175
[TBL] [Abstract][Full Text] [Related]
9. Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors.
Lai MZ; Song PR; Dou D; Diao YY; Tong LJ; Zhang T; Xie H; Li HL; Ding J
Acta Pharmacol Sin; 2020 Mar; 41(3):415-422. PubMed ID: 31316181
[TBL] [Abstract][Full Text] [Related]
10. Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor.
Gomez EB; Ebata K; Randeria HS; Rosendahl MS; Cedervall EP; Morales TH; Hanson LM; Brown NE; Gong X; Stephens J; Wu W; Lippincott I; Ku KS; Walgren RA; Abada PB; Ballard JA; Allerston CK; Brandhuber BJ
Blood; 2023 Jul; 142(1):62-72. PubMed ID: 36796019
[TBL] [Abstract][Full Text] [Related]
11. Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma.
Li CJ; Jiang C; Liu Y; Bell T; Ma W; Ye Y; Huang S; Guo H; Zhang H; Wang L; Wang J; Nomie K; Zhang L; Wang M
Mol Cancer Ther; 2019 Feb; 18(2):267-277. PubMed ID: 30413649
[TBL] [Abstract][Full Text] [Related]
12. Targeting Btk/Etk of prostate cancer cells by a novel dual inhibitor.
Guo W; Liu R; Bhardwaj G; Yang JC; Changou C; Ma AH; Mazloom A; Chintapalli S; Xiao K; Xiao W; Kumaresan P; Sanchez E; Yeh CT; Evans CP; Patterson R; Lam KS; Kung HJ
Cell Death Dis; 2014 Sep; 5(9):e1409. PubMed ID: 25188519
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma.
Wu H; Wang W; Liu F; Weisberg EL; Tian B; Chen Y; Li B; Wang A; Wang B; Zhao Z; McMillin DW; Hu C; Li H; Wang J; Liang Y; Buhrlage SJ; Liang J; Liu J; Yang G; Brown JR; Treon SP; Mitsiades CS; Griffin JD; Liu Q; Gray NS
ACS Chem Biol; 2014 May; 9(5):1086-91. PubMed ID: 24556163
[TBL] [Abstract][Full Text] [Related]
14. Orally bioavailable BTK PROTAC active against wild-type and C481 mutant BTKs in human lymphoma CDX mouse models.
Lim YS; Yoo SM; Patil V; Kim HW; Kim HH; Suh B; Park JY; Jeong NR; Park CH; Ryu JH; Lee BH; Kim P; Lee SH
Blood Adv; 2023 Jan; 7(1):92-105. PubMed ID: 36269842
[TBL] [Abstract][Full Text] [Related]
15. Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis.
Cinar M; Hamedani F; Mo Z; Cinar B; Amin HM; Alkan S
Leuk Res; 2013 Oct; 37(10):1271-7. PubMed ID: 23962569
[TBL] [Abstract][Full Text] [Related]
16. Myricetin suppresses p21-activated kinaseĀ 1 in human breast cancer MCF-7 cells through downstream signaling of the Ī²-catenin pathway.
Jiao D; Zhang XD
Oncol Rep; 2016 Jul; 36(1):342-8. PubMed ID: 27122002
[TBL] [Abstract][Full Text] [Related]
17. A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk
Gui F; Jiang J; He Z; Li L; Li Y; Deng Z; Lu Y; Wu X; Chen G; Su J; Song S; Zhang YM; Yun CH; Huang X; Weisberg E; Zhang J; Deng X
Br J Pharmacol; 2019 Dec; 176(23):4491-4509. PubMed ID: 31364164
[TBL] [Abstract][Full Text] [Related]
18. Synergistic effect of cucurbitacin E and myricetin on Anti-Non-Small cell lung cancer: Molecular mechanism and therapeutic potential.
Zhang J; Aray B; Zhang Y; Bai Y; Yuan T; Ding S; Xue Y; Huang X; Li Z
Phytomedicine; 2023 Mar; 111():154619. PubMed ID: 36706697
[TBL] [Abstract][Full Text] [Related]
19. Discovery of 5-Phenoxy-2-aminopyridine Derivatives as Potent and Selective Irreversible Inhibitors of Bruton's Tyrosine Kinase.
Lee E; Cho H; Lee DK; Ha J; Choi BJ; Jeong JH; Ryu JH; Kang JS; Jeon R
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33126415
[TBL] [Abstract][Full Text] [Related]
20. SY-1530, a highly selective BTK inhibitor, effectively treats B-cell malignancies by blocking B-cell activation.
Wang L; Sun Y; Liu X; Li H; Lu C; Yang R; Yang C; Li B
Cancer Biol Med; 2021 Jul; 19(7):995-1007. PubMed ID: 34264564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
